ArticleThe Journal of antimicrobial chemotherapy2025
Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Genomic epidemiology reveals geographically structured co-circulation of AFR10 and AFR13Microbial genomics · 2026Article
- Molecular insights and antibiotic resistance genes characterization in clinical Vibrio cholera isolates from patients in Peshawar, Pakistan.Molecular biology reports · 2026Article
- Genomic analysis of Vibrio cholerae in Western Kenya (2015-2023) reveals persistence of pandemic ST69 and presence of the European-associated ST8 lineage.BMC genomics · 2026Article
- Integrated Phenotypic and Genomic Analysis of Antimicrobial Resistance, Virulence, and Phylogeny inMicroorganisms · 2026Article
- Genomic analysis and antimicrobial resistance ofMicrobial genomics · 2025Article
- Antimicrobial Resistance in the Era of Climate Change: Why We Should All Embrace and Integrate the One Health Approach in Clinical Practice?Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIn mid-2021, a global surge in cholera cases was reported. This study characterized Vibrio cholerae O1 isolates obtained from faecal samples of cholera-positive cases during the 2022 cholera outbreak in Kenya.
methodsA total of 202 V. cholerae were confirmed through serogroup and serotype characterization by slide agglutination. Susceptibility testing was done using the Kirby-Bauer disc diffusion method, and ESBL production confirmed using the double-disc synergy test. WGS was performed on Illumina and ONT platforms, followed by bioinformatics analysis.
resultsAll the isolates were identified as V. cholerae O1 of Ogawa serotype, with 99% classified as MDR and 98.5% positive for ESBL production. Notably, the isolates were resistant to azithromycin, one of the recommended antibiotics for cholera treatment. MDR was linked to the acquisition of an IncC plasmid (pVCMLK181) carrying seven resistance genes, including mph(A), mph(E) and msr(E), which confer resistance to azithromycin, and the blaPER-7 ESBL gene. Resistance to nalidixic acid was associated with mutations in QRDRs of gyrA and parC. The isolates also carried SXT/R391-like ICE, ICEVchInd5 featuring a 10 kb deletion and mapped to the 7PET-AFR13 lineage. Phylogenetic analysis revealed a close relationship to other highly drug-resistant AFR13 strains reported in Tanzania, Comoros and Mayotte.
conclusionsThe high prevalence of multidrug resistance in cholera isolates emphasizes the need for continuous surveillance to monitor the evolution of MDR V. cholerae O1 strains and calls for consideration of deployment of alternative management and prevention options including oral cholera vaccines and long-term improvement of water, sanitation and hygiene (WASH) infrastructure and practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.